Dr. Shore on Immunotherapies for Prostate Cancer

Neal D. Shore, MD
Published: Thursday, Jun 20, 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Shore believes that the oncology community is getting close to significant breakthroughs in this space. In 2010, sipuleucel-T represented a tremendous breakthrough as the first immunotherapy approved for any metastatic solid tumor. As ipilimumab has been approved for metastatic melanoma, Shore notes that he's excited for data from two phase III trials looking at ipilimumab in advanced prostate cancer.

Unlike sipuleucel-T, ipilimumab is a checkpoint inhibitor, Shore says, and takes the break off of the immune system to let the T cells work in an unchecked way. PROSTVAC is similar to sipuleucel-T in that it is a T cell potentiator, directly stimulating T cells to work more effectively.

Shore says he is excited about preliminary studies exploring better checkpoint inhibitor therapies with fewer side effects and the possibility of combining immunotherapies.

<<< View more from the 2013 ASCO Annual Meeting

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Shore believes that the oncology community is getting close to significant breakthroughs in this space. In 2010, sipuleucel-T represented a tremendous breakthrough as the first immunotherapy approved for any metastatic solid tumor. As ipilimumab has been approved for metastatic melanoma, Shore notes that he's excited for data from two phase III trials looking at ipilimumab in advanced prostate cancer.

Unlike sipuleucel-T, ipilimumab is a checkpoint inhibitor, Shore says, and takes the break off of the immune system to let the T cells work in an unchecked way. PROSTVAC is similar to sipuleucel-T in that it is a T cell potentiator, directly stimulating T cells to work more effectively.

Shore says he is excited about preliminary studies exploring better checkpoint inhibitor therapies with fewer side effects and the possibility of combining immunotherapies.

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x